Keep in touch

Access more affordable valganciclovir through the Medicines Patent Pool/Roche agreement

Background: The Agreement between MPP and Roche

On August 5 2013, The Medicines Patent Pool (MPP) announced an agreement with Swiss pharmaceutical company Roche to increase access to valganciclovir, an important easy-to-take oral medicine to treat cytomegalovirus (CMV). CMV is a viral infection that can cause blindness in people living with HIV. The MPP/Roche agreement has a two-phased approach to increase access to valganciclovir:

  • First, a price reduction that will significantly improve access to Roche’s valganciclovir for people living with HIV in 138 developing countries by making it up to 90% cheaper than current prices.
  • Second, the MPP and Roche will enter into licensing and technology transfer negotiations to encourage the availability of quality generic versions of valganciclovir.

The full text of the agreement is available here [pdf].

The price of valganciclovir under the agreement

The price negotiated by the MPP for valganciclovir with Roche is 250 CHF per pack (approx. 203 EUR/275 USD) plus VAT on an ex-Works Roche, Basel basis. Costs such as freight and insurance are not included. The minimum order size is 40 packs of valganciclovir; each pack contains 60 tablets of valganciclovir 450mg.

How to benefit from this price

Contact the Medicines Patent Pool

If an entity wishes to benefit from the discounted price, it should sign an Acknowledgement Letter (available below). Through this letter the entity states that it is an eligible “Organisation” as defined in the agreement, acknowledges receipt of a copy of the Agreement, and agrees to be bound by the terms applicable to such an Organisation. The relevant obligations relate primarily to:

  • The geographical scope for the use of Roche’s valganciclovir (138 countries, See Annex 1) and,
  • That such use should be to treat and/or prevent CMV infection in relation to HIV therapy.

To receive a copy of the Acknowledgement Letter, click on one of the following files:

Contact Mr Chan Park the MPP’s General Counsel (gro.looptnetapsenicidemnull@krapc), if the above files do not work.

Contact Roche

Once the Acknowledgement Letter has been signed and sent to MPP, the organisation should contact Roche directly to order valganciclovir, via the information below:

Nicole Steiner
F. Hoffmann-La Roche Ltd, Basel
Building 237/2. 17
CH 4303 Switzerland
Email: moc.ehcornull@reniets.elocin
Phone: +41 61 688 88 46

The organisation shall place orders directly with Roche and copy Mr Sandeep Juneja (gro.looptnetapsenicidemnull@ajenujs) Business Development Director of the MPP.


Eligibility Criteria

Eligibility to benefit from this agreement, per the agreement between the MPP and Roche [pdf], is limited to not-for-profit HIV treatment organisations, including:

  • Those financed by national governments
  • The Global Fund to Fight AIDS, Tuberculosis and Malaria
  • The United States Presidents Emergency Plan for AIDS Relief (PEPFAR)
  • UNITAID
  • Médecins Sans Frontières
  • Any similar organisation identified by MPP and accepted by Roche

 

Annex 1 – List of countries included in this agreement

  1. Afghanistan
  2. Albania
  3. Algeria
  4. American Samoa
  5. Angola
  6. Antigua and Barbuda
  7. Argentina
  8. Armenia
  9. Azerbaijan
  10. Bangladesh
  11. Belarus
  12. Belize
  13. Benin
  14. Bhutan
  15. Bolivia
  16. Bosnia and Herzegovina
  17. Botswana
  18. Burkina Faso
  19. Burundi
  20. Cambodia
  21. Cameroon
  22. Cape Verde
  23. Central African Republic
  24. Chad
  25. Chile
  26. China
  27. Comoros
  28. Congo, Dem. Rep.
  29. Congo, Rep.
  30. Costa Rica
  31. Cote d’Ivoire
  32. Cuba
  33. Djibouti
  34. Dominica
  35. Dominican Republic
  36. Ecuador
  37. Egypt, Arab Rep.
  38. El Salvador
  39. Equatorial Guinea
  40. Eritrea
  41. Ethiopia
  42. Fiji
  43. Gabon
  44. Gambia, The
  45. Georgia
  46. Ghana
  47. Grenada
  48. Guatemala
  49. Guinea
  50. Guinea-Bissau
  51. Guyana
  52. Haiti
  53. Honduras
  54. India
  55. Indonesia
  56. Iran, Islamic Rep.
  57. Iraq
  58. Jamaica
  59. Jordan
  60. Kazakhstan
  61. Kenya
  62. Kiribati
  63. Korea, Dem. Rep.
  64. Kosovo
  65. Kyrgyz Republic
  66. Lao PDR
  67. Latvia
  68. Lebanon
  69. Lesotho
  1. Liberia
  2. Libya
  3. Lithuania
  4. Macedonia, FYR
  5. Madagascar
  6. Malawi
  7. Malaysia
  8. Maldives
  9. Mali
  10. Marshall Islands
  11. Mauritania
  12. Mauritius
  13. Micronesia, Fed. States
  14. Moldova
  15. Mongolia
  16. Montenegro
  17. Morocco
  18. Mozambique
  19. Myanmar
  20. Namibia
  21. Nepal
  22. Nicaragua
  23. Niger
  24. Nigeria
  25. Pakistan
  26. Palau
  27. Panama
  28. Papua New Guinea
  29. Paraguay
  30. Peru
  31. Philippines
  32. Rwanda
  33. Samoa
  34. Sao Tome and Principe
  35. Senegal
  36. Serbia
  37. Seychelles
  38. Sierra Leone
  39. Solomon Islands
  40. Somalia
  41. South Africa
  42. South Sudan
  43. Sri Lanka
  44. St. Lucia
  45. St. Vincent and the Grenadines
  46. Sudan
  47. Suriname
  48. Swaziland
  49. Syrian Arab Republic
  50. Tajikistan
  51. Tanzania
  52. Thailand
  53. Timor-Leste
  54. Togo
  55. Tonga
  56. Tunisia
  57. Turkmenistan
  58. Tuvalu
  59. Uganda
  60. Ukraine
  61. Uruguay
  62. Uzbekistan
  63. Vanuatu
  64. Venezuela, RB
  65. Vietnam
  66. West Bank and Gaza
  67. Yemen, Rep.
  68. Zambia
  69. Zimbabwe

This page is also available in: French, Spanish